EP1814616A1 — Automatic injector
Assigned to Sid Technologies LLC · Expires 2007-08-08 · 19y expired
What this patent protects
An injector is automatic in that the needle insertion into the injection site (e.g., a patient's skin) is triggered by the user or caregiver, the insertion is automatic, the following delivery is automatically initiated upon needle insertion, and the needle is shielded automatica…
USPTO Abstract
An injector is automatic in that the needle insertion into the injection site (e.g., a patient's skin) is triggered by the user or caregiver, the insertion is automatic, the following delivery is automatically initiated upon needle insertion, and the needle is shielded automatically after the end of delivery. Preferably the user does not see the needle prior to, during, or after injection. The injector includes a proximal and distal housings and a needle shield arranged to slide on the distal housing. The injector has a driver arranged to move the syringe to cause the needle penetration, to inject the drug, and subsequently to release the shield. The syringe needle is shielded and the shield locked automatically after delivery is completed. The patient does not experience any injector force on the tissue during injection. The injector has built in patient safety features.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.